Advertisement

Role of Autologous Stem Cell Transplantation in Multiple Myeloma

  • Jean-Luc Harousseau
Part of the Contemporary Hematology book series (CH)

Introduction

High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) was introduced in the treatment of multiple myeloma (MM) 20 years ago1,2and its role is still controversial. The use of peripheral blood stem cells instead of bone marrow has markedly improved feasibility and for newly diagnosed MM transplant-related mortality is 1–2% in fit patients with a normal renal function and younger than 65 years. In this group of patients, randomized studies have shown the superiority of ASCT compared with conventional chemotherapy. Therefore, until now, ASCT is considered the standard of care in this population of patients. However, it is currently challenged by the introduction of novel agents such as thalidomide, bortezomib, and lenalidomide. When they are used in combination with dexamethasone or with chemotherapy, these agents appear to yield results that are comparable to those achieved with ASCT. The question is now to determine whether novel agents should replace...

Keywords

Overall Survival Multiple Myeloma Complete Remission Autologous Stem Cell Transplantation Conventional Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.PubMedGoogle Scholar
  2. 2.
    Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–872.PubMedGoogle Scholar
  3. 3.
    Attal M, Harousseau JL, Stoppa AM et al. For the Intergroupe Français du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Child JA, Morgan GJ, Davies FE et al. Medical research council adult leukemia working party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.PubMedCrossRefGoogle Scholar
  5. 5.
    Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998; 92: 3131–3136.PubMedGoogle Scholar
  6. 6.
    Fermand JP, Katsahian S, Divine M et al. High-dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.PubMedCrossRefGoogle Scholar
  7. 7.
    Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.PubMedCrossRefGoogle Scholar
  8. 8.
    Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.PubMedCrossRefGoogle Scholar
  9. 9.
    Blade J, Rosinol L, Sureda A et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative groupe PETHEMA. Blood 2005; 106: 3755–3759.PubMedCrossRefGoogle Scholar
  10. 10.
    Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.PubMedCrossRefGoogle Scholar
  11. 11.
    Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282.PubMedGoogle Scholar
  12. 12.
    Kumar S, Lacy MQ, Dispenzieri A et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161–167.PubMedCrossRefGoogle Scholar
  13. 13.
    Harousseau JL, Milpied N, Laporte JP et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 3131–3136.Google Scholar
  14. 14.
    Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.PubMedGoogle Scholar
  15. 15.
    Attal M, Harousseau JL, Facon T et al. Intergroupe Francophone du Myelome: Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.PubMedCrossRefGoogle Scholar
  16. 16.
    Cavo M, Tosi P, Zamagni E et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J. Clin Oncol 2007; 25: 2434–2441.PubMedCrossRefGoogle Scholar
  17. 17.
    Sonneveld P, Van Der Holt B, Segeren CM et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Deutch Cooperative Group HOVaN 24 trial. Haematologica 2007; 92: 928–935.PubMedCrossRefGoogle Scholar
  18. 18.
    Barlogie B, Tricot G, Rabmussen E et al. Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and post-transplantation consolidation therapies. Blood 2006; 107: 2633–2638.PubMedCrossRefGoogle Scholar
  19. 19.
    Moreau P, Hullin C, Garban F et al. Tandem autologous stem cell transplantation in high risk de novo multiple myeloma: Final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397–403.PubMedCrossRefGoogle Scholar
  20. 20.
    Rajkumar V, Blaad E, Vesole D et al. Phase III clinical trial of Thalidomide plus Dexamethasone compared with Dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436.PubMedCrossRefGoogle Scholar
  21. 21.
    Cava M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39.CrossRefGoogle Scholar
  22. 22.
    Goldschmidt H, Sonneveld P, Breitkreuz I et al. HOVON 50/GMMG-HD3 trial: Phase III study on the effect of thalidomide combined with high-dose melphalan in myeloma patients up to 65 years. Blood 2005; 106: 128a (abstract).Google Scholar
  23. 23.
    Macro M, Divine M, Uzunban Y et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: A randomized trial. Blood 2006; 108: 22a (abstract).Google Scholar
  24. 24.
    Jagannath S, Durie B, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783.PubMedCrossRefGoogle Scholar
  25. 25.
    Oakervee HE, PoHat R, Curry N et al. PAD combination therapy (PS34l, doxoru-bicin and dexamethasone) for untreated multiple myeloma. Br J Haematol 2005; 755–762.Google Scholar
  26. 26.
    Popat R, Oakervee HE, Curry N et al. Reduced dose PAD (PS 341, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005; 106: 717a (abstract).CrossRefGoogle Scholar
  27. 27.
    Harousseau JL, Attal M. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006; 91: 1498–1505.PubMedGoogle Scholar
  28. 28.
    Barlogie B, Tricot G, Rasmussen E et al. Total therapy incorporating Velcade into upfront management of multiple myeloma: Comparison with TT2+thalidomide. Blood 2005; 106: 337a (abstract).Google Scholar
  29. 29.
    Wang M, Delaballe K, Giralt S et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005; 106: 231a (abstract).Google Scholar
  30. 30.
    Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050–4053.PubMedCrossRefGoogle Scholar
  31. 31.
    Attal M, Harousseau JL, Leyvras S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006: 15: 3289–3294.CrossRefGoogle Scholar
  32. 32.
    Spencer A, Prince M, Roberts AW et al. First analysis of the Australian leukaemia and lymphoma group trial of thalidomide and alternate day prednisone following autologous stem cell transplantation for patients with multiple myeloma. Blood 2006; 108: 22a (abstract).Google Scholar
  33. 33.
    Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.PubMedCrossRefGoogle Scholar
  34. 34.
    Siegel DS, Desikan KR, Nehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.PubMedGoogle Scholar
  35. 35.
    Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.PubMedCrossRefGoogle Scholar
  36. 36.
    Palumbo A, Triolo S, Argentin C. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.PubMedGoogle Scholar
  37. 37.
    Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose Melphalan improves survival of myeloma patients aged 50–70: Results of a randomized controlled trial. Blood; 2004: 3052–3057.Google Scholar
  38. 38.
    Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; 370: 1209–1218PubMedCrossRefGoogle Scholar
  39. 39.
    Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.PubMedCrossRefGoogle Scholar
  40. 40.
    Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and renal failure. Leukemia 2000; 14: 1310–1313.PubMedCrossRefGoogle Scholar
  41. 41.
    San Miguel J, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. Hematol J 2000; 1: 28–36.CrossRefGoogle Scholar
  42. 42.
    Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 66–75.Google Scholar
  43. 43.
    Vesole D, Tricot G, Jagannath S et al. Autotransplant in multiple myeloma: What have we learned? Blood 1996; 88: 838–847.PubMedGoogle Scholar
  44. 44.
    Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by Fish analysis and serum B2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.PubMedCrossRefGoogle Scholar
  45. 45.
    Tricot G, Spencer T, Sawyer J et al. Predicting long-term (~5 years) event-free survival in multiple myeloma patients following planned tandem autotransplant. Br J Haematol 2002; 116: 211–217.PubMedCrossRefGoogle Scholar
  46. 46.
    Shaughnessy J, Jacobson J, Sawyer J et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 2003; 101: 3849–3856.PubMedCrossRefGoogle Scholar
  47. 47.
    Fassas AT, Spencer T, Sawyer J et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041–1047.PubMedCrossRefGoogle Scholar
  48. 48.
    Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68.PubMedCrossRefGoogle Scholar
  49. 49.
    Gertz M, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14) (q13;q32), t(4;14) (p16.3;q32), and 17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.PubMedCrossRefGoogle Scholar
  50. 50.
    Jaksic W, Trudel S, Chang H et al. Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069–7073.PubMedCrossRefGoogle Scholar
  51. 51.
    Chang H, Qi C, Yi QL et al. p53 gene deletion detected by fluorescence in situ hybridisation is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358–360.PubMedCrossRefGoogle Scholar
  52. 52.
    Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489–3495.PubMedCrossRefGoogle Scholar
  53. 53.
    Palumbo A, Bringhen S, Caravita T et al. Oral Melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825–831.PubMedCrossRefGoogle Scholar
  54. 54.
    Mateos MV, Hernandez JM, Gutierrez WC et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a mul-ticenter phase l/II study. Blood 2006, online.Google Scholar
  55. 55.
    Palumbo A, Falco P, Falcone A et al. Oral revlimid plus melphalan and prednisone for newly diagnosed multiple myeloma: Results of a multicenter phase l/II study. Blood 2006; online.Google Scholar
  56. 56.
    Lacy M, Gertz M, Dispenzieri A et al. Lenalidomide plus dexamethasone in newly diagnosed myeloma: Response to therapy, time to progression and survival Lancet 2006; 367: 825–831.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jean-Luc Harousseau
    • 1
  1. 1.Centre Hospitalier Universitaire Hotel-DieuPlace Alexis RicordeauFrance

Personalised recommendations